Recursion's phase 2 programs are far more likely to fail than to succeed, if history is any guide. Sure, the company has multiple shots on goal.

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs ...

What programming languages like R and Python are to data science, ... Recursion is also joining the party and will be the first third-party addition to the BioNeMo platform, ...

More than 6,300 pounds of Burmese python were tracked and removed by the team, which has removed more than 40,000 pounds of invasive snake across a 200-square-mile area since 2013.

Programming Background: The course involves solving programming assignments in Python. You must be comfortable with Python programming. This includes basic control structures in Python: conditional ...

In the end, the original Python file contains the changes added by GPT-4. The code is available on GitHub , and the developer says the technique could be applied to other programming languages.

Recursion Pharmaceuticals, Inc. With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio ...

Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs. The proceeds will help the former Fierce 15 ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors ...